| Cubicin (daptomycin) / Merck (MSD) |
NCT00055198: Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria |
|
|
| Terminated | 3 | 75 | NA | daptomycin | Cubist Pharmaceuticals LLC | Gram-Positive Bacterial Infections | 01/04 | 01/04 | | |
NCT00093067: Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus |
|
|
| Completed | 3 | | NA | daptomycin | Cubist Pharmaceuticals LLC | Bacterial Endocarditis, Bacteremia | 11/04 | 02/05 | | |
NCT00770341: A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) |
|
|
| Completed | 3 | 122 | NA | Daptomycin 4 mg/kg, MK3009, Comparator: vancomycin, Daptomycin 6 mg/kg | Merck Sharp & Dohme LLC | Staphylococcal Infection | 02/10 | 02/10 | | |
DAVASAB, NCT01515020: Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia |
|
|
| Terminated | 3 | 10 | Europe | vancomycin monotherapy, intravenous therapy, daptomycin monotherapy | Assistance Publique - Hôpitaux de Paris, Novartis | Nosocomial Infection, Healthcare-associated Infection | 06/13 | 07/14 | | |
| Completed | 3 | 167 | Europe | Fosfomycin 2gr/6h iv, Daptomycin 10mg/kg/24h iv | Miquel Pujol, Hospital Universitari de Bellvitge | Staph Aureus Methicillin Resistant Bacteremia | 01/18 | 01/18 | | |
